Info

Medarex Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of fully human antibody-based therapeutic product candidates. As of December 31, 2007, over 40 antibody product candidates generated from the Company’s UltiMAb technology are in human clinical trials, or have had regulatory applications submitted for such trials. Eight of the advanced product candidates, in which Medarex has an economic interest through co-promotion/profit sharing rights, royalties and/or equity ownership, are in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Seven of these late-stage product candidates were generated through the use of its UltiMAb technology. In addition to the antibody candidates in Phase III trials, multiple product candidates in Phase II, Phase I and preclinical testing are being developed by Medarex alone, by Medarex jointly with its partners, or separately by its partners.(Source: 10-K)